Business
Vir Biotechnology to Participate in Upcoming Investor Conferences
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following
About this update from Vir Biotechnology, Inc.
[{"type":"text","content":" SAN FRANCISCO--(BUSINESS WIRE)--\nVir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March:\n\n\n\nTD Cowen 46th Annual Health Care Conference: Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Monday, March 2, 2026, at 3:10 p.m. ET/12:10 p.m. PT in Boston, Massachusetts.\n\n\n\nLeerink Partners Global Healthcare Conference: Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 10, 2026, at 1:40 p.m. ET/10:40 a.m. PT in Miami, Florida.\n\n\n\nBarclays 28th Annual Global Healthcare Conference: Members of management will be available for one-on-one meetings on Thursday, March 12, 2026, in Miami, Florida.\n\n\n\nLive webcasts of the fireside chats will be available at https://investors.vir.bio and will be archived for 30 days.\n\n\nAbout Vir Biotechnology, Inc.\n\n\nVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.\n\n\nVir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20260226768056/en/\n\nMedia Contact\nCaren Scannell\nDirector, Communications\[email protected]\n\n\nInvestor Contact\nKiki Patel, PharmD\nHead of Investor Relations\[email protected]\n\n\nSource: Vir Biotechnology, Inc.","length":4268,"tagName":"div"}]